Figure 3. NCAPD2 prognosis in 33 cancers was analyzed using Kaplan-Meier survival and univariate Cox analysis. (A) Kaplan-Meier survival curve of NCAPD2 in high- and low-expression groups for OS in ACC, KIRP, LGG, LIHC, LUAD, MESO, PAAD, READ, SARC, SKCM, THYM, UCEC, and UVM. Univariate Cox regression analysis comparing NCAPD2 expression and (B) overall survival, and (C) disease-specific survival in 33 cancers.